Skip to main content

Table 3 Medications used to treat Crohn’s disease prior to the diagnosis of hepatosplenic T-cell lymphoma (HSTCL) among unique cases

From: Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn’s disease medications and hepatosplenic T-cell lymphoma

Medication Number of cases with exposure reported, n (%) (n = 37) Mean cumulative dose, mg (minimum - maximum)a Mean duration of use, years (minimum - maximum)a Mean number of infusions or injections (minimum - maximum)a
Biologics 28 (76%)    
Adalimumab 8 (22%) 920 (800 to 1040) 1.5 (120 days to 2.6 years) 11.5 (10 to 13)
n = 2 n = 2 n = 2
Infliximaba 27 (73%) 41 (10 to 120) mg/kg 1.8 (1 day to 6 years) 9 (1 to 24)
n = 7 n = 12 n = 17
Natalizumab 1 (3%) NR NR 3
Ustekinumab 1 (3%) NR NR NR
Certolizumab pegol 0    
Anti-metabolites 365 (97%)    
6-mercaptopurine 20 (54%) 94,508 (3,900 to 212,160) 4.8 (39 days to 8 years)  
n = 4 n = 10
Azathioprine 23 (62%) 192,108 (1,450 to 301,125) 5.8 (39 days to 13.5 years)  
n = 3 n = 17
Aminosalicylates 15 (41%)    
Balsalazide 1 (3%) NR NR  
Mesalamine 13 (35%) NR 5 (n = 1)  
Sulfasalazine 2 (5%) NR 10 (n = 1)  
Corticosteroids 22 (59%)    
Budesonide 2 (5%) NR NR  
Hydrocortisone 1 (3%) NR NR  
Prednisone 14 (38%) NR NR  
Prednisolone 5 (14%) NR 13 (n = 1)  
Corticosteroid 4 (11%) NR 10 (n = 1)  
Other medications b 15 (41%)    
Antibioticsc 8 (22%) NR NR  
Cyclosporine 1 (3%) NR NR  
  1. aAmong those that reported this data. Cumulative dose excludes cases that only provided mg/kg dosing but did not provide patient weight in kilograms and those cases which reported a daily dose but did not report duration of treatment. bExcluding vitamin/mineral supplements. cThe antibiotics used included ciprofloxacin, doxycycline, metronidazole, nitrofurantoin, and piperacillin/tazobactam. HSTCL, hepatosplenic T-cell lymphoma; NR, not reported.